Tablet for oral use. One tablet per intake, once daily (approximately at the same time).
The product is administered outside a meal (in the interval between meals or 15 min prior to meal or fluid intake), the tablets should be held in mouth until complete dissolution. For young children (aged 1 month to 3 years old), the tablet is recommended to be dissolved in a small amount (1 tablespoon) of drinking water of room temperature.

Tablet for oral use. Placebo using Anaferon for children scheme.

Tablet for oral use. One tablet per intake, once daily (approximately at the same time).
The product is administered outside a meal (in the interval between meals or 15 min prior to meal or fluid intake), the tablets should be held in mouth until complete dissolution. For young children (aged 1 month to 3 years old), the tablet is recommended to be dissolved in a small amount (1 tablespoon) of drinking water of room temperature.
Anaferon for children: Tablet for oral use.

Anaferon for Children

Tablet for oral use. Placebo using Anaferon for children scheme.
Placebo: Tablet for oral use.

Placebo

Total

Sex: Female, Male

Race and Ethnicity Not Collected

Region of Enrollment

Time From Taking the First Dose of the Study Drug to the Onset of Influenza/ARVI Symptoms.

Based on medical records. Influenza/ARVI criteria are the following: febrile/subfebrile body temperature, presence at least one flu-like nonspecific symptom (decreased activity/weakness, headache, and chills), and at least one respiratory symptom (runny nose, nasal stuffiness, hoarseness/husky voice, sore throat, and cough).

Percentage of Children Not Falling Ill With Influenza or Another ARVI.

Based on medical records. Percentage of children with the symptoms of a respiratory or ear-nose-throat bacterial infection requiring antibacterial therapy.

Percentage of Children With the Symptoms Requiring Antibacterial Therapy.

Based on medical records. Percentage of children hospitalized for influenza/ARVI or their complications.

Percentage of Children Requiring Hospitalized for Influenza/ARVI.

Based on medical records. Presence and type of adverse events, their severity, relation to investigational drug, outcomes.

Presence and Type of Adverse Events (AE).

Overall Study

Michael Putilovskiy, MD, PhD, Clinical and Medical Department Director

Preventive Medicine

Anaferon for children

Municipal Autonomous Institution "Children's City Clinical Hospital No. 11"

Regional budgetary health care institution "Regional Children's Clinical Hospital"

Republican Children's Clinical Hospital of the Ministry of Health of the Udmurt Republic

Federal State Budgetary Educational Institution of Higher Education "Kazan Medical University" of the Ministry of Healthcare of the Russian Federation

Kazan Federal University

Federal Budget Institution of Science "Central Research Institute of Epidemiology" of The Federal Service on Customers' Rights Protection and Human Well-being Surveillance

Federal State Budgetary Educational Institution of Higher Education "Pirogov Russian National Research Medical University" of the Ministry of Healthcare of the Russian Federation

State Federal-Funded Educational Institution of Higher Professional Training I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

LLC Center for Vaccine Prevention "DIAVAKS"

Limited Liability Company "Gubernskiy lekar'"

Limited Liability Company "MDP-Medical Group"

Federal State Budgetary Educational Institution of Higher Education "Orenburg State Medical University" of the Ministry of Healthcare of the Russian Federation

Municipal Health Care Institution "City Child Health Clinical Polyclinic №5"

Municipal Budgetary Health Care Institutions "Semashko City Hospital №1 Rostov-on-Don "

Municipal budgetary health care institution "Children's city polyclinic №4"

St. Petersburg State Budgetary Healthcare Institution "Children's City Polyclinic No. 44"

St. Petersburg State Budgetary Health Care Institution "Сity Polyclinic №44"

Federal State Budgetary Educational Institution of Higher Education "St. Petersburg State Pediatric Medical Academy" of Ministry of Health of Russian Federation

St. Petersburg State Budgetary Healthcare Institution "Children's City Polyclinic No. 35"

St. Petersburg State Budgetary Healthcare Institution "Children's City Hospital No. 22"

Samara Regional Children's Sanatorium "Yunost'"

State Budgetary Institution of Health of the Samara Region "Samara City Children's Clinical Hospital No. 1 named after N.N. Ivanova"

Limited Liability Company "DNA Research Center"

Regional State Autonomous Healthcare Institution "Children's Hospital №1"

Siberian State Medical University

Bashkir State Medical University

Volgograd State Medical University/Departmental Clinical Hospital at Volgograd-1 Station of Russian Railways

Volgograd State Medical University/Volgograd Regional Clinical Hospital # 1

Yaroslavl State Medical University/Children's Clinic # 5

Yaroslavl State Medical University/Clinical Hospital # 8 (Children's Clinic # 1)

Yaroslavl State Medical University/Department of Infectious Diseases, Epidemiology and Children's Diseases

Yaroslavl State Medical University/Regional Children's Clinical Hospital # 8 (Children's Clinic # 2)

Family polyclinic № 6

Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI

International Multicenter Double-bind Placebo-controlled Randomized Parallel-group Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other Acute Respiratory Viral Infections in Children During the Peaks of Seasonal Morbidity

Materia Medica Holding

bola

антибактериски

antibacterial

bola/антибактериски

Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI

Најкомплетната база на податоци за лековити билки поддржана од науката